increased PSAD (p[ <0.001) were both independent predictors of CSC. Analysis of ROC curves yielded areas under the curve of 0.723 (%freePSA) and 0.717 (PSAD). A PSAD cutoff of 0.1 yielded a sensitivity of 79%, specificity of 50%, PPV of 33%, and NPV of 88%. A %free PSA cutoff of 20% yielded sensitivity of 83%, specificity of 45%, PPV of 45%, and NPV of 83%. Importantly, among 37 (24.3% of cohort with both variables available) patients with both PSAD <0.1 and %free PSA >20%, there were 0 clinically significant cancers detected on biopsy.
INTRODUCTION AND OBJECTIVES: The 2008 United States
Preventive Services Task Force (USPSTF) guidelines recommended against screening patients older than 75 years with PSA testing. The recommendation in 2012 further expanded these criteria to recommend against screening for prostate cancer based on PSA in all patients. It remains unclear how these changes impact public perception and participation in screening programs. We sought to compare prostate cancer screening participation before and after the 2012 USPSTF guidelines.
METHODS: We conduct a state funded, free to participants, prostate cancer screening program. All participants present with the desire to screen for prostate cancer with PSA. Our cohort consisted of 7, 950 voluntary screening encounters at various sites in our county. These sites consisted of our outpatient clinic, community health centers, churches, fire and police departments. Patients were divided into two groups and compared based on the major guideline change in RESULTS: Total patient encounters declined from 4,545 to 3,405 after the 2012 USPSTF screening guidelines. New patient screenings declined from 2,662 to 1,126. An increased number of patients reported a positive family history of prostate and/or breast cancer. The percentage of participants with a smoking history decreased from 51.33% to 46.33%. We found no significant difference in marital status, IPSS, PSA.
CONCLUSIONS: Our study is the first to date reviewing PSA test participation after the 2012 USPSTF guidelines in a cohort of participants primarily presenting for prostate cancer screening. In our cohort we demonstrate a decrease in prostate cancer screening after the 2012 USPSTF recommendations. How this decrease in PSA testing will affect prostate cancer specific mortality is unknown. The guidelines in 2018 were updated to recommend individualized, patient-specific routine PSA testing in patients aged 55 to 69. How this revision to the guidelines will affect prostate cancer screening remains to be seen. Community education in this area is essential and the urologic community must lead public discourse on prostate cancer screening. INTRODUCTION AND OBJECTIVES: Multi-parametric MRI (mpMRI) is growing as a screening approach for prostate cancer due to trials such as PROMIS and PRECISION demonstrating high sensitivity and negative predictive values. Unfortunately, implementation of mpMRI programs is complicated in practice due to additional costs, complexity, learning curve, procedure time, and experience required for adequate interpretation and reproducible results. Many men are also contraindicated to MRI due to concerns with renal function, claustrophobia, or ferromagnetic implants. This work aims to compare the sensitivity and specificity of mpMRI with the novel high-resolution microultrasound imaging modality, which maintains the workflow, simplicity and low cost of ultrasound and can be used to target biopsies in realtime without the need for MRI.
METHODS: Data from 5 sites was aggregated, totaling 280 subjects presenting for ExactVu micro-ultrasound guided biopsy with available mpMRI studies. Samples in all subjects were taken from mpMRI targets and micro-ultrasound targets, with up to 12 systematic samples filled in. mpMRI targets were sampled cognitively at 4/5 sites using the micro-ultrasound system and with either a software-fusion system or cognitively using micro-ultrasound at the 5th site. Clinically significant cancer was considered any Gleason Sum > 6 and targeted samples were taken for PI-RADS > 2 or PRI-MUS 1 > 2 lesions.
RESULTS: mpMRI demonstrated strong sensitivity (83%), with slightly weaker NPV (69%). Micro-ultrasound sensitivity (95%) and NPV (82%) were both higher. However, micro-ultrasound was considerably less specific (17% vs 25% for mpMRI) and both modalities showed a relatively poor PPV of 43-44%.
CONCLUSIONS: Micro-ultrasound's high sensitivity makes it an attractive option for both screening and targeted biopsy, even relative to the more widely studied mpMRI. Further larger-scale studies are required to ensure these early results are repeatable. The relatively lower specificity suggest micro-ultrasound is not yet able to exclude biopsy in as many men, though the higher sensitivity indicates the confidence may be higher in the men it does exclude. 
